A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business Business Description Precipio, Inc., and its subsidiaries, (collectively, “we”, “us”, “our”, the “Company” or “Precipio”) is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services aim to deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. We develop innovative technologies in our laboratory where we design, test, validate, and use these products clinically. We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field. We then commercialize these technologies as proprietary products that serve the global laboratory community in furtherance of our mission to eliminate or greatly reduce the prevalence of misdiagnoses.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 23M | 19M | 15M | 9.4M | 8.8M | - |
| Net Income | -1.3M | -4.3M | -5.9M | -12M | -8.5M | -14M |
| EPS | $-0.81 | $-2.93 | $-4.51 | $-10.73 | $-8.00 | $-17.00 |
| Free Cash Flow | 589K | 216K | -3.7M | -8.0M | -7.3M | -7.6M |
| ROIC | -17.8% | -34.6% | -39.9% | -73.7% | -34.7% | -94.5% |
| Gross Margin | 44.8% | 40.8% | 39.6% | 26.7% | 27.0% | - |
| Debt/Equity | 0.01 | 0.07 | 0.05 | 0.05 | 0.00 | 0.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.1M | -4.2M | -7.6M | -13M | -9.6M | -9.1M |
| Operating Margin | -9.1% | -22.7% | -50.1% | -136.0% | -108.6% | - |
| ROE | -9.1% | -32.3% | -40.6% | -74.9% | -34.7% | -98.8% |
| Shares Outstanding | 2M | 1M | 1M | 1M | 1M | 1M |
Precipio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 83.4x vs a median of 37.3x. The company's 5-year average gross margin is 33.5%.
Precipio, Inc. (PRPO) has a 5-year average return on invested capital (ROIC) of -55.5%. This is below average and may indicate limited pricing power.
Precipio, Inc. (PRPO) has a market capitalization of $49M. It is classified as a small-cap stock.
Precipio, Inc. (PRPO) does not currently pay a regular dividend.
Precipio, Inc. (PRPO) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
Precipio, Inc. (PRPO) reported annual revenue of $19 million in its most recent fiscal year, based on SEC EDGAR filings.
Precipio, Inc. (PRPO) has a net profit margin of -23.1%. The company is currently unprofitable.
Precipio, Inc. (PRPO) generated $216 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Precipio, Inc. (PRPO) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Precipio, Inc. (PRPO) reported earnings per share (EPS) of $-2.93 in its most recent fiscal year.
Precipio, Inc. (PRPO) has a return on equity (ROE) of -32.3%. A negative ROE may indicate losses or negative equity.
Precipio, Inc. (PRPO) has a 5-year average gross margin of 33.5%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for Precipio, Inc. (PRPO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Precipio, Inc. (PRPO) has a book value per share of $8.26, based on its most recent annual SEC filing.